Pharos iBio Participates as Invited Speaker at Korea-Australia Life Science Symposium

Pharos iBio participated as a speaker at the 3rd Joint Symposium of the Australian Society for Biochemistry and Molecular Biology (ASBMB) and the Korean Society for Biochemistry and Molecular Biology (KSBMB), held at the University of Sydney in Australia.

Kyutae Kim, President and Chief Business Officer (CBO) of the Australian branch, participated as an invited speaker at the 3rd ASBMB-KSBMB Joint Symposium held at the University of Sydney, Australia on the 28th. Pharos iBio

According to Pharos iBio on September 29, the symposium was held in conjunction with the global life sciences academic event 'ComBio 2026.' The event gathered researchers and biotech industry stakeholders from both Korea and Australia to share the latest research achievements and technology trends and to discuss opportunities for research and industrial cooperation between the two countries.

Kyutae Kim, CEO and Chief Business Officer (CBO) of the Australian branch, participated as a speaker in the 'Industry Collaboration' session, introducing Pharos iBio's artificial intelligence (AI)-based drug discovery capabilities and global business development strategy. He particularly emphasized the company’s open innovation strategy, highlighting its proprietary AI drug discovery platform and in-house R&D capabilities to expand joint research with domestic and global pharmaceutical and biotech companies and research institutes, and to enhance the commercial potential of drug development through global partnerships.

Since the establishment of its Australian subsidiary in 2019, Pharos iBio has continued joint research and clinical collaboration with institutions such as the University of Sydney, the Australasian Leukaemia & Lymphoma Group (ALLG), the Peter MacCallum Cancer Centre, the Walter and Eliza Hall Institute of Medical Research (WEHI), and the Children’s Cancer Institute Australia (CCIA). The company is utilizing Australia as one of its global R&D and open innovation hubs for clinical trials and collaborative research on key pipelines, including Lasmotinib (PHI-101).

From this year, Pharos iBio has been implementing its 'Pharos iBio 2.0' strategy, focusing on strengthening internal research capabilities and expanding open innovation. The company has been accelerating external collaborations through government R&D initiatives and domestic and global joint research. In fact, this year, Pharos iBio was consecutively selected for research and development projects promoted by the Ministry of Health and Welfare, the Korea Drug Development Fund (KDDF), and the Ministry of SMEs and Startups. Last month, it also signed a formal joint development contract with Kolon Pharmaceuticals for the next-generation epidermal growth factor receptor (EGFR) inhibitor, 'PHI-701,' expanding the scope of collaboration beyond candidate discovery to include preclinical and clinical development.

This content was produced with the assistance of AI translation services.